Tillmann Uhlig

• Kjørholt, Kaja Eriksrud; Paulshus Sundlisæter, Nina; Aga, Anna-Birgitte; Sexton, Joseph; Olsen, Inge Christoffer & Fremstad, Hallvard [Show all 22 contributors for this article] (2024). Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial. The Lancet Rheumatology. doi: 10.1016/S2665-9913(24)00021-3.
• Liu, Jianyang; Idborg, Helena; Korotkova, Marina; Lend, Kristina; van Vollenhoven, Ronald & Lampa, Jon [Show all 16 contributors for this article] (2024). Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis. Arthritis Research & Therapy. ISSN 1478-6354. 26(1). doi: 10.1186/s13075-024-03295-9.
• Holten, Karen; Paulshus Sundlisæter, Nina; Sexton, Joseph; Nordberg, Lena Bugge; Uhlig, Till & Kvien, Tore Kristian Aaserud [Show all 10 contributors for this article] (2024). Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity. RMD Open. ISSN 2056-5933. 10(1). doi: 10.1136/rmdopen-2023-003486.
• Lend, Kristina; Koopman, Frieda A.; Lampa, Jon; Jansen, Gerrit; Hetland, Merete L. & Uhlig, Till [Show all 18 contributors for this article] (2023). Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial. Arthritis & Rheumatology. ISSN 2326-5191. p. 1–14. doi: 10.1002/art.42730. Full text in Research Archive
• Dures, Emma; Farisoğulları, Bayram; Santos, Eduardo José Ferreira; Molto, Anna; Feldthusen, Caroline & Harris, Claire [Show all 26 contributors for this article] (2023). 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases. ISSN 0003-4967. doi: 10.1136/ard-2023-224514.
• Skinnes, Mari Nilsen; Moe, Rikke Helene; Johansen, Thomas; Lyby, Peter Solvoll; Dahl, Kjersti & Eid, Idun [Show all 17 contributors for this article] (2023). Work Ability in the Year after Rehabilitation—Results from the RehabNytte Cohort. Journal of Clinical Medicine. ISSN 2077-0383. 12(23). doi: 10.3390/jcm12237391. Full text in Research Archive
• Uhlig, Till; Karoliussen, Lars Fridtjof; Sexton, Joseph; Kvien, Tore Kristian Aaserud; Haavardsholm, Espen A. & Hammer, Hilde Berner (2023). Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study. RMD Open. ISSN 2056-5933. 9(4). doi: 10.1136/rmdopen-2023-003600. Full text in Research Archive
• Uhlig, Till; Karoliussen, Lars Fridtjof; Sexton, Joseph; Provan, Sella Aarrestad; Kvien, Tore Kristian Aaserud & Haavardsholm, Espen A. [Show all 7 contributors for this article] (2023). Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study. Rheumatology. ISSN 1462-0324. 62(12), p. 3886–3892. doi: 10.1093/rheumatology/kead124. Full text in Research Archive Show summary

  Objectives In patients with gout there is a lack of longitudinal studies on the course of work productivity. We explored longitudinal changes in and predictors of work productivity over 2 years. Methods Patients in the NOR-Gout observational study with a recent gout flare and serum urate (sUA) >360 µmol/l attended tight-control visits during escalating urate lowering therapy according to a treat-to-target strategy. From the Work Productivity and Activity Impairment (WPAI) questionnaire, scores for work productivity and activity impairment were assessed over 2 years together with the Beliefs about Medicines Questionnaire and a variety of demographic and clinical variables. Results At baseline patients had a mean age of 56.4 years and 95% were males. WPAI scores at baseline were 5.0% work missed (absenteeism), 19.1% work impairment (presenteeism), 21.4% overall work impairment and 32.1% activity impairment. Work productivity and activity impairment improved during the first months, and remained stable at 1 and 2 years. Comorbidities were not cross-sectionally associated with WPAI scores at baseline, but predicted worse work impairment and activity impairment at year 1. The Beliefs about Medicines Questionnaire subscale with concerns about medicines at baseline independently predicted worse overall work impairment and worse activity impairment at year 1. Conclusions In patients with gout who were intensively treated to the sUA target, work productivity and activity impairment were largely unchanged and at 1 year predicted by comorbidities and patient concerns about medication.

• Lillegraven, Siri; Paulshus Sundlisæter, Nina; Aga, Anna-Birgitte; Sexton, Joseph; Olsen, Inge Christoffer & Lexberg, Åse [Show all 19 contributors for this article] (2023). Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial. Annals of the Rheumatic Diseases. ISSN 0003-4967. 82(11), p. 1394–1403. doi: 10.1136/ard-2023-224476. Full text in Research Archive
• Parodis, Ioannis; Girard-Guyonvarc'h, Charlotte; Arnaud, Laurent; Distler, Oliver; Domján, Andrea & Van Den Ende, Cornelia H M [Show all 25 contributors for this article] (2023). EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. Annals of the Rheumatic Diseases. ISSN 0003-4967. doi: 10.1136/ard-2023-224416.
• Østergaard, Mikkel; Van Vollenhoven, Ronald F; Rudin, Anna; Hetland, Merete Lund; Schrumpf, Marte & Nordström, Dan C [Show all 45 contributors for this article] (2023). Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Annals of the Rheumatic Diseases. ISSN 0003-4967. 82(10), p. 1286–1295. doi: 10.1136/ard-2023-224116. Full text in Research Archive
• Uhlig, Till; Karoliussen, Lars Fridtjof; Sexton, Joseph; Kvien, Tore Kristian Aaserud; Haavardsholm, Espen A. & Taylor, W.J. [Show all 7 contributors for this article] (2023). Beliefs about medicines in gout patients: results from the NOR-Gout 2-year study. Scandinavian Journal of Rheumatology. ISSN 0300-9742. doi: 10.1080/03009742.2023.2213507. Full text in Research Archive
• Chen, Leanne; Gamble, Gregory D.; Horne, Anne; Drake, Jill; Doyle, Anthony J. & Uhlig, Till [Show all 8 contributors for this article] (2023). Changes in Tophus Composition During Urate-Lowering Therapy: A Dual-Energy Computed Tomography Study. Arthritis care & research. ISSN 2151-464X. doi: 10.1002/acr.25084.
• Sumpter, Nicholas A; Takei, Riku; Cadzow, Murray; Topless, Ruth; Phipps-Green, Amanda & Murphy, Rinki [Show all 39 contributors for this article] (2022). Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With Gout. Arthritis & Rheumatology. ISSN 2326-5191. 75(5), p. 816–825. doi: 10.1002/art.42393.
• Uhlig, Till; Karoliussen, Lars Fridtjof; Sexton, Joseph; Kvien, Tore Kristian; Haavardsholm, Espen A. & Perez-Ruiz, F. [Show all 7 contributors for this article] (2022). Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study. Clinical Rheumatology. ISSN 0770-3198. 41, p. 3817–3823. doi: 10.1007/s10067-022-06416-4. Full text in Research Archive
• Smedslund, Geir; Kotar, Martina & Uhlig, Till (2022). Sarcoidosis with musculoskeletal manifestations: systematic review of non-pharmacological and pharmacological treatments. Rheumatology International. ISSN 0172-8172. 42(12), p. 2109–2124. doi: 10.1007/s00296-022-05171-8. Full text in Research Archive
• Lend, Kristina; van Vollenhoven, Ronald F; Lampa, Jon; Lund Hetland, Merete; Haavardsholm, Espen A. & Nordström, Dan [Show all 18 contributors for this article] (2022). Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial. The Lancet Rheumatology. 4(10), p. e688–e698. doi: 10.1016/S2665-9913(22)00186-2. Full text in Research Archive
• Hammer, Hilde Berner; Rollefstad, Silvia Christin Hellerud; Semb, Anne Grete; Jensen, Gro Elisabeth; Karoliussen, Lars Fridtjof & Terslev, L [Show all 9 contributors for this article] (2022). Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study. RMD Open. ISSN 2056-5933. 8(2), p. 1–5. doi: 10.1136/rmdopen-2022-002348. Full text in Research Archive
• Uhlig, Till; Karoliussen, Lars Fridtjof; Sexton, Joseph; Kvien, Tore Kristian; Haavardsholm, Espen A. & Perez-Ruiz, Fernando [Show all 7 contributors for this article] (2022). One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study. Arthritis Research & Therapy. ISSN 1478-6354. 24:88, p. 1–11. doi: 10.1186/s13075-022-02772-3. Full text in Research Archive
• Sundlisæter, Nina Beate Paulshus; Sundin, Ulf Gunnar; Aga, Anna-Birgitte; Sexton, Joseph; Hammer, Hilde Berner & Uhlig, Till [Show all 9 contributors for this article] (2022). Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study. RMD Open. ISSN 2056-5933. 8(1), p. 1–6. doi: 10.1136/rmdopen-2021-002013. Full text in Research Archive Show summary

  Objective To investigate limiting factors of American College of Rheumatology (ACR)/EULAR Boolean remission in rheumatoid arthritis (RA), and compare patients who fulfil the criteria to patients who only partly fulfil the criteria, with respect to imaging inflammation and biologic disease modifying anti-rheumatic drug (DMARD) usage. Methods Patients with DMARD-naïve RA were treated according to current recommendations in the the ARCTIC trial (Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen). Limiting factors of reaching ACR/EULAR Boolean remission at 2 years were assessed. Imaging inflammation (ultrasound and MRI) in patients in remission was compared with patients failing to fulfil different components of the criteria. The OR of biologic therapy was calculated using logistic regression. Results Of 203 patients, 112 (55%) reached ACR/EULAR Boolean remission; 49 (24%) fulfilled three of four criteria. The main limiting factors were patient global assessment (PGA) (59%) and tender joints (22%). Imaging inflammation was not significantly different for patients in remission and patients not fulfilling the criteria due to elevated PGA and/or tender joints, but higher odds of using biologics (OR 3.63, 95% CI 1.73 to 7.61) were observed. Conclusions PGA and tender joints were the factors most often limiting achievement of ACR/EULAR Boolean remission. The level of imaging inflammation was not elevated in these patients compared with patients in remission, but the odds of using biologic DMARDs were higher. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

• Uhlig, Till; Eskild, Tron Hovind; Karoliussen, Lars Fridtjof; Sexton, Joseph; Kvien, Tore Kristian & Haavardsholm, Espen A. [Show all 8 contributors for this article] (2021). Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study. Rheumatology. ISSN 1462-0324. 61, p. S181–S185. doi: 10.1093/rheumatology/keab533. Full text in Research Archive Show summary

  Objectives: There is a lack of large longitudinal studies of urate deposition measured by dual-energy computed tomography (DECT) during urate lowering therapy (ULT) in people with gout. We explored longitudinal changes in DECT urate depositions during a treat-to-target strategy with ULT in gout. Methods: Patients with a recent gout flare and serum-urate (sUA) >360 µmol/l attended tight-control visits during escalating ULT. The treatment target was sUA <360 µmol/l, and <300 µmol/l if presence of tophi.A DECT scanner (General Electric Discovery CT750 HD) acquired data from bilateral forefeet and ankles at baseline and after one and two years. Images were scored in known order, using the semi-quantitative Bayat method, by one experienced radiologist who was blinded to serum urate and clinical data. Four regions were scored: the first metatarsophalangeal (MTP1) joint, the other joints of the toes, the ankles and midfeet, and all tendons in the feet and ankles. Results: DECT was measured at baseline in 187 of 211 patients. The mean (S.D.) serum urate level (μmol/l) decreased from 501 (80) at baseline to 311 (48) at 12 months, and 322 (67) at 24 months.DECT scores at all locations decreased during both the first and the second year (p< 0.001 for all comparisons vs baseline), both for patients achieving and not achieving the sUA treatment target. Conclusions: In patients with gout, urate depositions in ankles and feet as measured by DECT decreased both in the first and the second year, when patients were treated using a treat-to-target ULT strategy.

• Aldridge, Jonathan; Lundell, Anna-Carin; Andersson, Kerstin; Mark, Linda; Hetland, Merete Lund & Østergaard, Mikkel [Show all 17 contributors for this article] (2021). Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis. Clinical and Experimental Rheumatology. ISSN 0392-856X. 40(7), p. 1393–1402. doi: 10.55563/clinexprheumatol/idogmj. Show summary

  Objectives: In early rheumatoid arthritis (eRA) plasma levels of specific chemokines have been shown to correlate with disease activity. However, it is unclear whether pre-treatment chemokine levels can predict disease remission at week 24, and it is not known how biological treatments with different modes of action affect plasma chemokine levels in patients with untreated eRA. Methods: This study included 347 Swedish patients with untreated eRA from the larger NORD-STAR randomised treatment trial. Here, eRA patients were treated with methotrexate combined with either prednisolone, anti-TNF (certolizumab-pegol), CTLA-4Ig (abatacept) or anti-IL6 receptor (tocilizumab). The primary clinical outcome was remission by clinical disease activity index (CDAI) defined as CDAI ≤ 2.8. Disease activity was assessed by CDAI, DAS28-ESR, DAS28-CRP, swollen joint counts, tender joint counts, ESR and CRP. The plasma concentrations of 14 chemokines were measured at baseline and after 24 weeks of treatment by bead-based immunoassay or ELISA. Results: Baseline plasma concentrations of CXCL10, CXCL8, CXCL9, CXCL11, CXCL5 and CCL2 correlated with baseline disease activity measures. After 24 weeks of treatment, plasma levels of CXCL10, CXCL8, CXCL9, CXCL11 and CXCL13 decreased in all treatment groups except in patients treated with anti-IL6 receptor. In multivariate factor analysis, plasma chemokine levels at baseline could not differentiate patients who attained remission by week 24 from those who did not in any of the treatment groups. Conclusions: In patients with untreated eRA, plasma levels of several chemokines correlate with disease activity at baseline but cannot predict remission after 24 weeks of treatment with methotrexate combined with prednisolone, anti‑TNF, CTLA‑4Ig or anti‑IL6R.

• Maugesten, Øystein Gunnar; Ohrndorf, Sarah; Christensen, Barbara Therese Slatkovsky; Kvien, Tore Kristian; Uhlig, Till & Bos-Haugen, Ida Kristin (2021). Associations between Fluorescence Optical Imaging and Magnetic Resonance Imaging and symptoms in hand osteoarthritis. Rheumatology. ISSN 1462-0324. doi: 10.1093/rheumatology/keab085. Show summary

  Objectives: To investigate whether Fluorescence Optical Imaging (FOI) enhancement and Magnetic Resonance Imaging (MRI)-defined synovitis are associated with pain and physical function in hand osteoarthritis (OA) patients. Methods: Bilateral FOI scans and MRI of the dominant hand were available for 221 patients. Finger joints were examined for tenderness on palpation. Pain in individual finger joints during the last 24 h and last 6 weeks and hand pain intensity by the Australian/Canadian hand index and Numeric Rating Scale were self-reported. On joint level, we applied logistic regression with generalized estimating equations to examine whether FOI enhancement and MRI-defined synovitis were associated with pain in the same joint. On subject level, we applied linear regression to assess whether FOI and MRI sum scores were associated with pain intensity and physical function. Results: Metacarpophalangeal and thumb base joints were excluded from analyses due to little/no FOI enhancement. Finger joints with FOI enhancement on the composite image had higher odds (95% confidence interval) of pain during the last 6 weeks (grade 1: 1.4 (1.2-1.6), grade 2-3: 2.1 (1.7-2.6)). Similar results were found for joint pain during the last 24 h and joint tenderness in fingers. Numerically stronger associations were found between MRI-defined synovitis and finger joint pain/tenderness. FOI and MRI sum scores demonstrated no/weak associations with hand pain and physical function. Conclusion: FOI enhancement and MRI-defined synovitis were associated with pain in the same finger joint. None of the imaging modalities demonstrated consistent associations with pain, stiffness and physical function on subject level.

• Stockfelt, Marit; Lundell, Anna-Carin; Hetland, Merete Lund; Østergaard, Mikkel; Uhlig, Till & Schrumpf, Marte [Show all 19 contributors for this article] (2021). Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial. Arthritis Research & Therapy. ISSN 1478-6354. 23(1). doi: 10.1186/s13075-021-02556-1. Full text in Research Archive Show summary

  Background: The type I interferon (IFN) gene signature is present in a subgroup of patients with early rheumatoid arthritis (RA). Protein levels of IFNα have not been measured in RA and it is unknown whether they associate with clinical characteristics or treatment effect. Methods: Patients with early untreated RA (n = 347) were randomized to methotrexate combined with prednisone, certolizumab-pegol, abatacept, or tocilizumab. Plasma IFNα protein levels were determined by single molecular array (Simoa) before and 24 weeks after treatment initiation and were related to demographic and clinical factors including clinical disease activity index, disease activity score in 28 joints, swollen and tender joint counts, and patient global assessment. Results: IFNα protein positivity was found in 26% of the patients, and of these, 92% were double-positive for rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). IFNα protein levels were reduced 24 weeks after treatment initiation, and the absolute change was similar irrespective of treatment. IFNα protein positivity was associated neither with disease activity nor with achievement of CDAI remission 24 weeks after randomization. Conclusion: IFNα protein positivity is present in a subgroup of patients with early RA and associates with double-positivity for autoantibodies but not with disease activity. Pre-treatment IFNα positivity did not predict remission in any of the treatment arms, suggesting that the IFNα system is distinct from the pathways of TNF, IL-6, and T-cell activation in early RA. A spin-off study of the NORD-STAR randomized clinical trial, NCT01491815 (ClinicalTrials), registered 12/08/2011, https://clinicaltrials.gov/ct2/show/NCT01491815 .

• Holten, Karen; Sundlisæter, Nina Beate Paulshus; Lillegraven, Siri; Sexton, Joseph; Nordberg, Lena Kristine Bugge & Moholt, Ellen [Show all 11 contributors for this article] (2021). Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment. Annals of the Rheumatic Diseases. ISSN 0003-4967. doi: 10.1136/annrheumdis-2021-220750. Full text in Research Archive Show summary

  Objectives: Fatigue is a frequent symptom in rheumatoid arthritis (RA) and has high impact on quality of life. We explored associations between disease activity and fatigue in patients with early RA during the initial 24 months of modern treat-to-target therapy and predictors of fatigue after 24 months of follow-up. Methods: Data were obtained from the treat-to-target, tight control Aiming for Remission in Rheumatoid Arthritis: a Randomised Trial Examining the Benefit of Ultrasound in a Clinical Tight Control Regime (ARCTIC) trial. Fatigue was measured on a visual analogue scale (VAS) from 0 to 100 mm and defined as clinically relevant if VAS was ≥20 mm. Baseline predictors of fatigue at 24 months were analysed by multivariable logistic regression. Results: 205 patients with fatigue data at baseline and 24 months were included. Median (25th, 75th percentiles) symptom duration was 5.4 months (2.8, 10.4), fatigue VAS 37.0 mm (13.0, 62.0) and mean Disease Activity Score (DAS) 3.4 (SD 1.1) at baseline. Prevalence of fatigue declined from 69% at baseline to 38% at 24 months. Fewer swollen joints (OR 0.92, 95% CI 0.87 to 0.98, p=0.006), lower power Doppler ultrasound score (OR 0.95, 95% CI 0.90 to 0.99, p=0.027) and higher patient global assessment (PGA) (OR 1.03, 95% CI 1.01 to 1.04, p<0.001) increased the risk of clinically relevant fatigue at 24 months. Not achieving remission at 6 months was associated with a higher risk of reporting fatigue at 24 months. Conclusions: Fatigue in patients with early RA was prevalent at disease onset, with a rapid and sustained reduction during treatment. Low objective disease activity and high PGA at baseline were predictors of clinically relevant fatigue at 24 months.

• Pettersen, Pernille Steen; Neogi, Tuhina; Magnusson, Karin; Mathiessen, Alexander; Hammer, Hilde Berner & Uhlig, Till [Show all 8 contributors for this article] (2021). Associations between joint pathologies and central sensitization in persons with hand osteoarthritis: Results from the Nor-Hand study. Rheumatology. ISSN 1462-0324. 61(6), p. 2316–2324. doi: 10.1093/rheumatology/keab708. Full text in Research Archive Show summary

  Objective: Pain sensitization is associated with pain severity in persons with hand osteoarthritis (OA). What contributes to pain sensitization is unclear. This study explores whether hand OA pathologies and symptom duration are related to central sensitization. Method: Participants with hand OA in the Nor-Hand study underwent bilateral hand radiography and ultrasound examination. Central sensitization was assessed with pressure pain thresholds (PPT) at remote sites (wrist, trapezius and tibialis anterior muscles) and temporal summation (TS). We examined whether hand OA pathologies, independent of each other, including structural severity (Kellgren-Lawrence sum score, presence of erosive hand OA), inflammatory severity (greyscale synovitis and power Doppler activity sum scores) and symptom duration, were related to central sensitization, adjusting for age, sex, body mass index, comorbidities and OA-severity of knee/hip. Results: In 291 participants (88% women, median age 61, IQR 57-66 years) Kellgren-Lawrence, greyscale synovitis and power Doppler activity sum scores were not associated with lower PPTs at remote sites. Persons with erosive hand OA had lower PPTs at the wrist (adjusted beta -0.75, 95%CI -1.32, -0.19) and tibialis anterior (adjusted beta -0.82, 95%CI -1.54, -0.09) and had greater TS (adjusted beta 0.56, 95%CI 0.12, 1.01) compared with persons with non-erosive disease. No associations were found for symptom duration. Conclusions: A person's overall amount of structural or inflammatory hand OA pathologies does not appear to drive central sensitization. Although persons with erosive hand OA showed greater signs of central sensitization, the small differences suggest that central sensitization is mainly explained by other factors than joint pathologies.

• Christensen, Ingrid Egeland; Lillegraven, Siri; Pawel, Mielnik; Bakland, Gunnstein; Loli, Liz Paucar & Sexton, Joseph [Show all 9 contributors for this article] (2021). Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study. Annals of the Rheumatic Diseases. ISSN 0003-4967. doi: 10.1136/annrheumdis-2021-221007. Full text in Research Archive Show summary

  Objectives: To estimate the incidence of serious infections (SIs) in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with tumour necrosis factor inhibitor (TNFi), and compare risk of SIs between patients with RA and PsA. Methods: We included patients with RA and PsA from the NORwegian-Disease Modifying Anti-Rheumatic Drug registry starting TNFi treatment. Crude incidence rates (IRs) and IR ratio for SIs were calculated. The risk of SIs in patients with RA and PsA was compared using adjusted Cox-regression models. Results: A total of 3169 TNFi treatment courses (RA/PsA: 1778/1391) were identified in 2359 patients. Patients with RA were significantly older with more extensive use of co-medication. The crude IRs for SIs were 4.17 (95% CI 3.52 to 4.95) in patients with RA and 2.16 (95% CI 1.66 to 2.81) in patients with PsA. Compared with the patients with RA, patients with PsA had a lower risk of SIs (HR 0.59, 95% CI 0.41 to 0.85, p=0.004) in complete set analysis. The reduced risk in PsA versus RA remained significant after multiple adjustments and consistent across strata based on age, gender and disease status. Conclusions: Compared with patients with RA, the risk of SIs was significantly lower in patients with PsA during TNFi exposure. Methods We included patients with RA and PsA from the NORwegian-Disease Modifying Anti-Rheumatic Drug registry starting TNFi treatment. Crude incidence rates (IRs) and IR ratio for SIs were calculated. The risk of SIs in patients with RA and PsA was compared using adjusted Cox-regression models. Results A total of 3169 TNFi treatment courses (RA/ PsA: 1778/1391) were identified in 2359 patients. Patients with RA were significantly older with more extensive use of co-medication. The crude IRs for SIs were 4.17 (95% CI 3.52 to 4.95) in patients with RA and 2.16 (95% CI 1.66 to 2.81) in patients with PsA. Compared with the patients with RA, patients with PsA had a lower risk of SIs (HR 0.59, 95% CI 0.41 to 0.85, p=0.004) in complete set analysis. The reduced risk in PsA versus RA remained significant after multiple adjustments and consistent across strata based on age, gender and disease status. Conclusions Compared with patients with RA, the risk of SIs was significantly lower in patients with PsA during TNFi exposure.

• Taylor, William J.; Dalbeth, Nicola; Saag, Kenneth; Singh, Jasvinder A.; Rahn, Elizabeth J. & Mudano, Amy S. [Show all 27 contributors for this article] (2021). Flare rate thresholds for patient assessment of disease activity states in Gout. Journal of Rheumatology. ISSN 0315-162X. 48(2), p. 293–298. doi: 10.3899/jrheum.191242.
• Jagpal, Aprajita; Rahn, Elizabeth J.; Mudano, Amy S.; Dalbeth, Nicola; Taylor, William J. & Saag, Kenneth G. [Show all 21 contributors for this article] (2021). Which factors predict discordance between a patient and physician on a gout flare? Rheumatology. ISSN 1462-0324. 60(2), p. 773–779. doi: 10.1093/rheumatology/keaa413.
• Uhlig, Till; Karoliussen, Lars Fridtjof; Sexton, Joseph; Borgen, Tove; Haavardsholm, Espen A. & Kvien, Tore Kristian [Show all 7 contributors for this article] (2021). 12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: Achievements of the urate target levels and predictors of obtaining this target. RMD Open. ISSN 2056-5933. 7(1). doi: 10.1136/rmdopen-2021-001628. Full text in Research Archive
• Lillegraven, Siri; Sundlisæter, Nina Beate Paulshus; Aga, Anna-Birgitte; Sexton, Joseph; Olsen, Inge Christoffer & Fremstad, Hallvard [Show all 21 contributors for this article] (2021). Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial. Journal of the American Medical Association (JAMA). ISSN 0098-7484. 325(17), p. 1755–1764. doi: 10.1001/jama.2021.4542. Show summary

  IMPORTANCE Sustained remission has become an achievable goal for patients with rheumatoid arthritis (RA) receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), but how to best treat patients in clinical remission remains unclear. OBJECTIVE To assess the effect of tapering of csDMARDs, compared with continuing csDMARDs without tapering, on the risk of flares in patients with RA in sustained remission. DESIGN, SETTING, AND PARTICIPANTS ARCTIC REWIND was a multicenter, randomized, parallel, open-label noninferiority study conducted in 10 Norwegian hospital-based rheumatology practices. A total of 160 patients with RA in remission for 12 months who were receiving stable csDMARD therapy were enrolled between June 2013 and June 2018, and the final visit occurred in June 2019. INTERVENTIONS Patients were randomly assigned to half-dose csDMARDs (n = 80) or stable-dose csDMARDs (n = 80). MAIN OUTCOMES AND MEASURES The primary end point was the proportion of patients with a disease flare between baseline and the 12-month follow-up, defined as a combination of Disease Activity Score (DAS) greater than 1.6 (threshold for RA remission), an increase in DAS score of 0.6 units or more, and at least 2 swollen joints. A disease flare could also be recorded if both the patient and investigator agreed that a clinically significant flare had occurred. A risk difference of 20% was defined as the noninferiority margin. RESULTS Of 160 enrolled patients (mean [SD] age, 55.1 [11.9] years; 66% female), 156 received the allocated therapy, of which 155 without any major protocol violations were included in the primary analysis population (77 receiving half-dose and 78 receiving stable-dose csDMARDs). Flare occurred in 19 patients (25%) in the half-dose csDMARD group compared with 5 (6%) in the stable-dose csDMARD group (risk difference, 18% [95% CI, 7%-29%]). Adverse events occurred in 34 patients (44%) in the half-dose group and 42 (54%) in the stable-dose group, none leading to study discontinuation. No deaths occurred. CONCLUSIONS AND RELEVANCE Among patients with RA in remission taking csDMARD therapy, treatment with half-dose vs stable-dose csDMARDs did not demonstrate noninferiority for the percentage of patients with disease flares over 12 months, and there were significantly fewer flares in the stable-dose group. These findings do not support treatment with half-dose therapy.

• Maugesten, Øystein Gunnar; Ohrndorf, S.; Glinatsi, D.; Ammitzbøll-Danielsen, M.; Kisten, Y. & Østergaard, M. [Show all 10 contributors for this article] (2020). Evaluation of three scoring methods for Fluorescence Optical Imaging in erosive hand osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage Open. ISSN 2665-9131. 1(3-4). doi: 10.1016/j.ocarto.2019.100017.
• Maugesten, Øystein Gunnar; Mathiessen, Alexander; Hammer, Hilde Berner; Hestetun, Sigrid Valen; Kvien, Tore Kristian & Uhlig, Till [Show all 8 contributors for this article] (2020). Validity and diagnostic performance of fluorescence optical imaging measuring synovitis in hand osteoarthritis: baseline results from the Nor-Hand cohort. Arthritis Research & Therapy. ISSN 1478-6354. 22(1). doi: 10.1186/s13075-020-02185-0. Full text in Research Archive
• Hetland, Merete Lund; Haavardsholm, Espen A.; Rudin, Anna; Nordström, Dan C.; Nurmohamed, Michael & Gudbjornsson, Bjorn [Show all 43 contributors for this article] (2020). Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial. The BMJ. ISSN 1756-1833. 371, p. 1–10. doi: 10.1136/bmj.m4328. Full text in Research Archive
• Sundin, Ulf Gunnar; Aga, Anna-Birgitte; Skare, Øivind; Nordberg, Lena Kristine Bugge; Uhlig, Till & Hammer, Hilde Berner [Show all 10 contributors for this article] (2020). Conventional versus ultrasound treat to target: No difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis. Rheumatology. ISSN 1462-0324. 59(9), p. 2550–2555. doi: 10.1093/rheumatology/kez674. Full text in Research Archive
• Provan, Sella Aarrestad; Michelsen, Brigitte; Sexton, Joseph; Uhlig, Till & Hammer, Hilde Berner (2020). Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy. RMD Open. ISSN 2056-5933. 6(3). doi: 10.1136/rmdopen-2020-001372.
• Meisters, Rachelle; Putrik, Polina; Ramiro, Sofia; Hifinger, Monika; Keszei, Andras P. & van Eijk-Hustings, Yvonne [Show all 46 contributors for this article] (2020). EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. Annals of the Rheumatic Diseases. ISSN 0003-4967. 79(11), p. 1423–1431. doi: 10.1136/annrheumdis-2020-217520.
• Hammer, Hilde Berner; Karoliussen, Lars Fridtjof; Terslev, Lene; Haavardsholm, Espen A; Kvien, Tore Kristian & Uhlig, Till (2020). Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study. Annals of the Rheumatic Diseases. ISSN 0003-4967. 79(11), p. 1500–1505. doi: 10.1136/annrheumdis-2020-217392.
• Hammer, Hilde Berner; Michelsen, Brigitte; Sexton, Joe; Uhlig, Till & Provan, Sella Aarrestad (2020). Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis. Clinical Rheumatology. ISSN 0770-3198. p. 1–11. doi: 10.1007/s10067-020-05402-y. Full text in Research Archive
• Norvang, Vibeke; Brinkmann, Gina Charlotte Hetland; Yoshida, Kazuki; Lillegraven, Siri; Aga, Anna-Birgitte & Sexton, Joseph Andrew [Show all 14 contributors for this article] (2020). Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-to-Target Strategies. Arthritis & Rheumatology. ISSN 2326-5191. 72(7), p. 1072–1081. doi: 10.1002/art.41232. Full text in Research Archive
• Pettersen, Pernille Steen; Neogi, Tuhina; Magnusson, Karin; Hammer, Hilde Berner; Uhlig, Till & Kvien, Tore Kristian [Show all 7 contributors for this article] (2020). Associations Between Radiographic and Ultrasound‐Detected Features in Hand Osteoarthritis and Local Pressure Pain Thresholds. Arthritis & Rheumatology. ISSN 2326-5191. 72(6), p. 966–971. doi: 10.1002/art.41199. Full text in Research Archive
• Bursill, David; Taylor, William J.; Terkeltaub, Robert; Kuwabara, Masanari; Merriman, Tony R. & Grainger, Rebecca [Show all 56 contributors for this article] (2019). Gout, Hyperuricemia, and Crystal-Associated Disease Network consensus statement regarding labels and definitions for disease elements in gout. Arthritis care & research. ISSN 2151-464X. 71(3), p. 427–434. doi: 10.1002/acr.23607.
• Richette, Pascal; Doherty, Michael; Pascual, Eliseo; Barskova, Victoria; Becce, Fabio & Castaneda, Johann [Show all 24 contributors for this article] (2019). 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Annals of the Rheumatic Diseases. ISSN 0003-4967. 79, p. 31–38. doi: 10.1136/annrheumdis-2019-215315.
• Putrik, Polina; Ramiro, Sofia; Guillemin, Francis; Péntek, Márta; Sivera, Francisca & Sokka, Tuulikki [Show all 52 contributors for this article] (2019). Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. Annals of the Rheumatic Diseases. ISSN 0003-4967. 78(11), p. 1472–1479. doi: 10.1136/annrheumdis-2019-215294.
• Bursill, David; Taylor, William J.; Terkeltaub, Robert; Abhishek, Abhishek; So, Alexander K. & Vargas-Santos, Ana Beatriz [Show all 78 contributors for this article] (2019). Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Annals of the Rheumatic Diseases. ISSN 0003-4967. 78(11), p. 1592–1600. doi: 10.1136/annrheumdis-2019-215933.
• Provan, Sella Aarrestad; Lillegraven, Siri; Sexton, Joseph; Angel, Kristin; Austad, Cathrine & Haavardsholm, Espen A. [Show all 8 contributors for this article] (2019). Trends in All-Cause and Cardiovascular Mortality in Patients With Incident Rheumatoid Arthritis: A 20-year Follow-Up Matched Case-Cohort Study. Rheumatology. ISSN 1462-0324. doi: 10.1093/rheumatology/kez371. Full text in Research Archive
• van Onna, Marloes; Putrik, Polina; Lie, Elisabeth; Kvien, Tore Kristian; Boonen, Annelies & Uhlig, Till (2019). What Do We Measure With 28-joint DAS in Elderly Patients? An Explorative Analysis in the NOR-DMARD Study. Rheumatology. ISSN 1462-0324. doi: 10.1093/rheumatology/kez490. Full text in Research Archive
• Hammer, Hilde Berner; Michelsen, Brigitte; Sexton, Joseph; Haugen, Ida Kristin; Provan, Sella Aarrestad & Haavardsholm, Espen A. [Show all 8 contributors for this article] (2019). Swollen, but not tender joints, are independently associated with ultrasound synovitis: Results from a longitudinal observational study of patients with established rheumatoid arthritis. Annals of the Rheumatic Diseases. ISSN 0003-4967. 78, p. 1179–1185. doi: 10.1136/annrheumdis-2019-215321.
• Pettersen, Pernille Steen; Neogi, Tuhina; Magnusson, Karin; Hammer, Hilde Berner; Uhlig, Till & Kvien, Tore Kristian [Show all 7 contributors for this article] (2019). Peripheral and Central Sensitization of Pain in Individuals With Hand Osteoarthritis and Associations With Self-Reported Pain Severity. Arthritis & Rheumatology. ISSN 2326-5191. 71(7), p. 1070–1077. doi: 10.1002/art.40850. Full text in Research Archive
• Provan, Sella Aarrestad; Austad, Cathrine; Halsaa, Vera; Hammer, Hilde Berner; Kvien, Tore Kristian & Uhlig, Till (2019). Fibromyalgia in patients with rheumatoid arthritis. A 10-year follow-up study, results from the Oslo Rheumatoid Arthritis Register. Clinical and Experimental Rheumatology. ISSN 0392-856X. 37(Supplement 116), p. S58–S62.
• Nordberg, Lena Kristine Bugge; Lillegraven, Siri; Aga, Anna-Birgitte; Sexton, Joseph; Olsen, Inge Christoffer & Lie, Elisabeth [Show all 11 contributors for this article] (2018). Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD Open. ISSN 2056-5933. 4(2), p. 11–17. doi: 10.1136/rmdopen-2018-000752. Full text in Research Archive
• Hammer, Hilde Berner; Michelsen, Brigitte; Provan, Sella Aarrestad; Sexton, Joseph; Lampa, Jon & Uhlig, Till [Show all 7 contributors for this article] (2018). Tender joint count may not reflect inflammatory activity in established rheumatoid arthritis patients: results from a longitudinal study. Arthritis care & research. ISSN 2151-464X. doi: 10.1002/acr.23815.
• Norvang, Vibeke; Sexton, Joseph; Kristianslund, Eirik; Olsen, Inge Christoffer; Uhlig, Till & Bakland, Gunnstein [Show all 13 contributors for this article] (2018). Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. RMD Open. ISSN 2056-5933. 4(2). doi: 10.1136/rmdopen-2018-000773. Full text in Research Archive
• Sundlisæter, Nina Beate Paulshus; Olsen, Inge Christoffer; Aga, Anna-Birgitte; Hammer, Hilde Berner; Uhlig, Till & Heijde, Desirée van der [Show all 9 contributors for this article] (2018). Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. Rheumatology. ISSN 1462-0324. 57(11), p. 2022–2031. doi: 10.1093/rheumatology/key202.
• Kiadaliri, A. A.; Uhlig, Till & Englund, M. (2018). Burden of gout in the Nordic region, 1990–2015: findings from the Global Burden of Disease Study 2015. Scandinavian Journal of Rheumatology. ISSN 0300-9742. 47(5), p. 410–417. doi: 10.1080/03009742.2017.1405461.
• Nordberg, Lena Kristine Bugge; Lillegraven, Siri; Aga, Anna-Birgitte; Sexton, Joseph; Lie, Elisabeth & Hammer, Hilde Berner [Show all 11 contributors for this article] (2018). The impact of ultrasound on the use and efficacy of intraarticular glucocorticoid injections in early rheumatoid arthritis: Secondary analyses from a randomized trial examining the benefit of ultrasound in a clinical tight control regimen. Arthritis & Rheumatology. ISSN 2326-5191. 70(8), p. 1192–1199. doi: 10.1002/art.40494.
• Uhlig, Till & Provan, Sella Aarrestad (2018). Treating fatigue in rheumatoid arthritis: does patient age matter? Drugs & Aging. ISSN 1170-229X. 35(10), p. 871–876. doi: 10.1007/s40266-018-0589-4.
• Verket, Nina Julie; Uhlig, Till; Sandvik, Leiv; Andersen, Marit Helen; Tanbo, Tom Gunnar & Qvigstad, Erik (2018). Health‐related quality of life in women with endometriosis, compared with the general population and women with rheumatoid arthritis. Acta Obstetricia et Gynecologica Scandinavica. ISSN 0001-6349. 97(11), p. 1339–1348. doi: 10.1111/aogs.13427.
• Sundlisæter, Nina Beate Paulshus; Aga, Anna-Birgitte; Olsen, Inge Christoffer; Hammer, Hilde Berner; Uhlig, Till & Heijde, Desirée van der [Show all 9 contributors for this article] (2018). Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: Associations to future good radiographic and physical outcomes. Annals of the Rheumatic Diseases. ISSN 0003-4967. 77(10), p. 1421–1425. doi: 10.1136/annrheumdis-2017-212830. Full text in Research Archive
• Michelsen, Brigitte; Uhlig, Till; Sexton, Joseph; Heijde, Desirée van der; Hammer, Hilde Berner & Kristianslund, Eirik [Show all 13 contributors for this article] (2018). Health-related quality of life in patients with psoriatic and rheumatoid arthritis: Data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls. Annals of the Rheumatic Diseases. ISSN 0003-4967. 77(9), p. 1290–1294. doi: 10.1136/annrheumdis-2018-213286. Full text in Research Archive
• Hifinger, Monika; Ramiro, Sofia; Putrik, Polina; van Eijk-Hustings, Yvonne; Woolf, Anthony & Smolen, Josef Sebastian [Show all 16 contributors for this article] (2018). The eumusc.net standards of care for rheumatoid arthritis: Importance and current implementation according to patients and healthcare providers in the Netherlands. Clinical and Experimental Rheumatology. ISSN 0392-856X. 36(2), p. 275–283.
• Hammer, Hilde Berner; Uhlig, Till; Kvien, Tore Kristian & Lampa, Jon (2018). Pain catastrophizing is strongly associated with subjective outcomes, but not with inflammatory assessments in rheumatoid arthritis patients. Arthritis care & research. ISSN 2151-464X. 70(5), p. 703–712. doi: 10.1002/acr.23339.
• Putrik, Polina; Ramiro, Sofia; Lie, Elisabeth; Michaud, Kaleb; Kvamme, Maria Knoph & Keszei, Andras P. [Show all 9 contributors for this article] (2018). Deriving common comorbidity indices from the MedDRA classification and exploring their performance on key outcomes in patients with rheumatoid arthritis. Rheumatology. ISSN 1462-0324. 57(3), p. 548–554. doi: 10.1093/rheumatology/kex440.
• Klokkerud, Mari; Dagfinrud, Hanne; Uhlig, Till; Dager, Turid Nygaard; Furunes, Kari Anita & Klokkeide, Åse [Show all 11 contributors for this article] (2018). Developing and testing a consensus-based core set of outcome measures for rehabilitation in musculoskeletal diseases. Scandinavian Journal of Rheumatology. ISSN 0300-9742. 47(3), p. 225–234. doi: 10.1080/03009742.2017.1347959.
• Uhlig, Till & Goll, Guro Løvik (2017). Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology. ISSN 1462-0324. 56, p. iv49–iv62. doi: 10.1093/rheumatology/kex276.
• Glinatsi, Daniel; Schrumpf, Marte; Rudin, Anna; Nordström, Dan C.; Haavardsholm, Espen A. & Gudbjörnsson, Björn [Show all 12 contributors for this article] (2017). Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: Study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study. Trials. ISSN 1745-6215. 18(161). doi: 10.1186/s13063-017-1891-x.
• Østerås, Nina; Kjeken, Ingvild; Smedslund, Geir; Moe, Rikke Helene; Christensen, Barbara Therese Slatkovsky & Uhlig, Till [Show all 7 contributors for this article] (2017). Exercise for Hand Osteoarthritis: A Cochrane Systematic Review. Journal of Rheumatology. ISSN 0315-162X. 44(12), p. 1850–1858. doi: 10.3899/jrheum.170424.
• Ogdie, Alexis R.; Taylor, William J.; Neogi, Tuhina; Fransen, Jaap; Jansen, Tim L. & Schumacher, H. Ralph [Show all 29 contributors for this article] (2017). Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard. Arthritis & Rheumatology. ISSN 2326-5191. 69(2), p. 429–438. doi: 10.1002/art.39959.
• Østerås, Nina; Kjeken, Ingvild; Smedslund, Geir; Moe, Rikke Helene; Christensen, Barbara Therese Slatkovsky & Uhlig, Till [Show all 7 contributors for this article] (2017). Exercise for hand osteoarthritis. Cochrane Database of Systematic Reviews. ISSN 1469-493X. 2017(1). doi: 10.1002/14651858.CD010388.pub2.
• Nordberg, Lena Kristine Bugge; Lillegraven, Siri; Lie, Elisabeth; Aga, Anna-Birgitte; Olsen, Inge Christoffer & Hammer, Hilde Berner [Show all 11 contributors for this article] (2017). Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria. Annals of the Rheumatic Diseases. ISSN 0003-4967. 76(2), p. 341–345. doi: 10.1136/annrheumdis-2015-208873.
• Austad, Cathrine; Kvien, Tore Kristian; Olsen, Inge Christoffer & Uhlig, Till (2017). Sleep disturbance in patients with rheumatoid arthritis is related to fatigue, disease activity, and other patient-reported outcomes. Scandinavian Journal of Rheumatology. ISSN 0300-9742. 46(2), p. 95–103. doi: 10.3109/03009742.2016.1168482.
• Provan, Sella Aarrestad; Olsen, Inge Christoffer; Austad, Cathrine; Haugeberg, Glenn; Kvien, Tore Kristian & Uhlig, Till (2017). Calcium supplementation and inflammation increase mortality in rheumatoid arthritis: A 15-year cohort study in 609 patients from the Oslo Rheumatoid Arthritis Register. Seminars in Arthritis & Rheumatism. ISSN 0049-0172. 46(4), p. 411–417. doi: 10.1016/j.semarthrit.2016.07.011.
• Hifinger, M.; Hiligsmann, M.; Ramiro, S; Watson, V.; Severens, J.L. & Fautrel, B. [Show all 17 contributors for this article] (2016). Economic considerations and patients’ preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. Annals of the Rheumatic Diseases. ISSN 0003-4967. 76, p. 126–132. doi: 10.1136/annrheumdis-2016-209202.
• Dalbeth, Nicola; Schumacher, H. Ralph; Fransen, Jaap; Neogi, Tuhina; Jansen, Tim L. & Brown, Melanie [Show all 26 contributors for this article] (2016). Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. Arthritis care & research. ISSN 2151-464X. 68(12), p. 1894–1898. doi: 10.1002/acr.22896.
• Richette, Pascal; Doherty, M.; Pascual, E.; Barskova, V.; Becce, F. & Castañeda-Sanabria, J. [Show all 24 contributors for this article] (2016). 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases. ISSN 0003-4967. 76, p. 29–42. doi: 10.1136/annrheumdis-2016-209707.
• Putrik, Polina; Ramiro, Sofia; Lie, Elisabeth; Keszei, Andras P.; Kvien, Tore Kristian & Heijde, Desirée van der [Show all 9 contributors for this article] (2016). Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. Rheumatology. ISSN 1462-0324. 55(7), p. 1217–1224. doi: 10.1093/rheumatology/kew048.
• Uhlig, Till; Eskild, Tron Hovind & Hammer, Hilde Berner (2016). Urinsyregikt - nytt innen diagnostikk og behandling. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 136(21), p. 1804–1807. doi: 10.4045/tidsskr.16.0147.
• Haavardsholm, Espen A.; Aga, Anna-Birgitte; Olsen, Inge Christoffer; Lillegraven, Siri; Hammer, Hilde Berner & Uhlig, Till [Show all 19 contributors for this article] (2016). Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. The BMJ. ISSN 1756-1833. 354. doi: 10.1136/bmj.i4205. Full text in Research Archive
• Aga, Anna-Birgitte; Hammer, Hilde Berner; Olsen, Inge Christoffer; Uhlig, Till; Kvien, Tore Kristian & Heijde, Desirée van der [Show all 19 contributors for this article] (2016). Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach. RMD Open. ISSN 2056-5933. 2(2). doi: 10.1136/rmdopen-2016-000325. Full text in Research Archive
• Ikdahl, Eirik; Rollefstad, Silvia Christin Hellerud; Wibetoe, Grunde; Olsen, Inge Christoffer; Berg, Inger Jorid & Hisdal, Jonny [Show all 11 contributors for this article] (2016). Predictive value of arterial stiffness and subclinical carotid atherosclerosis for cardiovascular disease in patients with rheumatoid arthritis. Journal of Rheumatology. ISSN 0315-162X. 43(9), p. 1622–1630. doi: 10.3899/jrheum.160053.
• Uhlig, Till; Lie, Elisabeth; Norvang, Vibeke; Lexberg, Åse; Rødevand, Erik & Krøll, Frode [Show all 9 contributors for this article] (2016). Achievement of remission and low disease activity definitions in patients with rheumatoid arthritis in clinical practice: Results from the Nor-Dmard study. Journal of Rheumatology. ISSN 0315-162X. 43(4), p. 717–724. doi: 10.3899/jrheum.151132. Show summary

  Objective. To examine the frequency of 6 definitions for remission and 4 definitions for low disease activity (LDA) after starting a disease-modifying antirheumatic drug (DMARD) in patients with rheumatoid arthritis (RA) in clinical practice, and to study whether predictors for achieving remission after 6 months are similar for these definitions. Methods. Remission and LDA were calculated according to the 28-joint Disease Activity Score (DAS28), the Clinical Disease Activity Index (CDAI), the Simplified Disease Activity Index (SDAI), the Routine Assessment of Patient Index Data (RAPID3), and both the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean remission definitions 3 and 6 months after 4992 DMARD prescriptions for patients enrolled in the NOR-DMARD, a 5-center Norwegian register. Prediction of remission after 6 months was also studied. Results. After 3 months, remission rates varied between definitions from 8.7% to 22.5% and for LDA from 35.5% to 42.7%, and increased slightly until 6 months of followup. DAS28 and RAPID3 gave the highest and ACR/EULAR, SDAI, and CDAI the lowest proportions for remission. Positive predictors for remission after 6 months were similar across the definitions and included lower age, male sex, short disease duration, high level of education, current nonsmoking, nonerosive disease, treatment with a biological DMARD, being DMARD-naive, good physical function, little fatigue, and LDA. Conclusion. In daily clinical practice, the DAS28 and RAPID3 definitions identified remission about twice as often as the ACR/EULAR Boolean, SDAI, and CDAI. Predictors of remission were similar across remission definitions. These findings provide additional evidence to follow treatment recommendations and treat RA early with a DMARD.

View all works in Cristin

• Uhlig, Till (2023). Ekspertenes beste råd mot urinsyregikt . [Newspaper]. Dagbladet.
• Uhlig, Till (2023). Bedre livskvalitet for pasienter med revmatiske sykdommer. [Newspaper]. Dagbladet.
• Uhlig, Till (2023). Ny studie: Rett behandling for urinsyregikt. [Internet]. Dagbladet.
• Uhlig, Till (2023). Kombinasjonsbehandling med biologiske og andre avanserte legemidler. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(14). doi: 10.4045/tidsskr.23.0517.
• Skattør, Marianne; Uhlig, Till & Risum, Kristine (2022). Revidering av fagprosedyren «Trening ved polymyositt og dermatomyositt».
• Skattør, Marianne; Uhlig, Till & Risum, Kristine (2022). Revidering av fagprosedyren «Trening ved polymyositt og dermatomyositt».
• Østergaard, Mikkel; van Vollenhoven, Ronald; Rudin, Anna; Hetland, Merete L.; Schrumpf, Marte & Nordström, Dan [Show all 44 contributors for this article] (2022). CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONAL THERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STAR TRIAL. Annals of the Rheumatic Diseases. ISSN 0003-4967. 81, p. 38–40.
• Lillegraven, Siri; Sundlisæter, Nina Paulshus; Aga, Anna-Birgitte; Sexton, Joe; Olsen, Inge Christoffer & Fremstad, Hallvard [Show all 21 contributors for this article] (2022). Drug Free Remission in Rheumatoid Arthritis: Data from the Randomized Controlled ARCTIC REWIND Trial. Arthritis & Rheumatology. ISSN 2326-5191. 74, p. 3970–3972. doi: 10.1002/art.42355.
• Maugesten, Øystein Gunnar; Mathiessen, Alexander; Hammer, Hilde Berner; Hestetun, Sigrid Valen; Kvien, Tore Kristian & Uhlig, Till [Show all 8 contributors for this article] (2021). Correction to: Validity and diagnostic performance of fluorescence optical imaging measuring synovitis in hand osteoarthritis: baseline results from the Nor-Hand cohort. Arthritis Research & Therapy. ISSN 1478-6354. 23. doi: 10.1186/s13075-021-02469-z.
• Sundlisæter, Nina Beate Paulshus; Aga, Anna-Birgitte; Olsen, Inge Christoffer; Hammer, Hilde Berner; Uhlig, Till & van der Heijde, Désirée [Show all 9 contributors for this article] (2021). Joint tenderness and ultrasound inflammation in DMARD-naïve patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases. ISSN 0003-4967. doi: 10.1136/annrheumdis-2021-220265.
• Kvamme, Maria Knoph; Lie, Elisabeth; Uhlig, Till; Moger, Tron Anders; Kvien, Tore Kristian & Kristiansen, Ivar Sønbø (2020). Erratum: Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A Markov model study based on two longitudinal observational studies (Rheumatology (2015 54 (1226-1235) DOI: 10.1093/rheumatology/keu460). Rheumatology. ISSN 1462-0324. 59(4). doi: 10.1093/rheumatology/kez609.
• Norvang, Vibeke; Kvien, Tore Kristian; Uhlig, Till; Lillegraven, Siri; Mjaavatten, Maria Dahl & Yoshida, Kazuki [Show all 8 contributors for this article] (2020). Reply. Arthritis & Rheumatology. ISSN 2326-5191. 72(8), p. 1407–1408. doi: 10.1002/art.41268.
• Hammer, Hilde Berner; Karoliussen, Lars Fridtjof; Terslev, Lene; Haavardsholm, Espen A.; Kvien, Tore Kristian & Uhlig, Till (2020). Response to: € Correspondence on € Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study'' by Hung et al. Annals of the Rheumatic Diseases. ISSN 0003-4967. doi: 10.1136/annrheumdis-2020-218908.
• Lillegraven, Siri; Sundlisæter, Nina Beate Paulshus; Aga, Anna-Birgitte; Sexton, Joseph; Olsen, Inge Christoffer & Fremstad, Hallvard [Show all 21 contributors for this article] (2020). TAPERING OF CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN SUSTAINED RHEUMATOID ARTHRITIS REMISSION: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL. Annals of the Rheumatic Diseases. ISSN 0003-4967. 79, p. 1012–1013. doi: 10.1136/annrheumdis-2020-eular.3090.
• Lillegraven, Siri; Sundlisæter, Nina Beate Paulshus; Aga, Anna-Birgitte; Sexton, Joseph; Olsen, Inge Christoffer & Lexberg, Åse [Show all 19 contributors for this article] (2020). STABLE VERSUS TAPERED AND WITHDRAWN TREATMENT WITH TUMOR NECROSIS FACTOR INHIBITOR IN RHEUMATOID ARTHRITIS REMISSION (ARCTIC REWIND): A RANDOMISED, OPEN-LABEL, PHASE 4, NON-INFERIORITY TRIAL. Annals of the Rheumatic Diseases. ISSN 0003-4967. 79, p. 14–15. doi: 10.1136/annrheumdis-2020-eular.1955.
• Gaffo, Angelo L.; Dalbeth, Nicola; Saag, Kenneth G.; Singh, Jasvinder A.; Rahn, Elizabeth J. & Mudano, Amy S. [Show all 27 contributors for this article] (2018). Brief Report: Validation of a Definition of Flare in Patients With Established Gout. Arthritis & Rheumatology. ISSN 2326-5191. 70(3), p. 462–467. doi: 10.1002/art.40381.
• Singh, Jasvinder A. & Uhlig, Till (2017). Chasing crystals out of the body: Will treat to serum urate target for gout help us get there? Annals of the Rheumatic Diseases. ISSN 0003-4967. 76(4), p. 629–631. doi: 10.1136/annrheumdis-2016-210436.
• Haavardsholm, Espen A.; Aga, Anna-Birgitte; Olsen, Inge Christoffer; Lillegraven, Siri; Hammer, Hilde Berner & Uhlig, Till [Show all 19 contributors for this article] (2016). Ultrasound in The Management of Rheumatoid Arthritis: Results from The Randomized Controlled Arctic Trial. Annals of the Rheumatic Diseases. ISSN 0003-4967. 75, p. 123–123. doi: 10.1136/annrheumdis-2016-eular.3042.
• Østerås, Nina; Kjeken, Ingvild; Smedslund, Geir; Moe, Rikke Helene; Christensen, Barbara Therese Slatkovsky & Uhlig, Till [Show all 7 contributors for this article] (2017). Exercise for hand osteoarthritis (Review). Cochrane Collaboration. ISSN 1469-493X. Show summary

  Hand osteoarthritis (OA) is a prevalent joint disease that may lead to pain, stiffness and problems in performing hand-related activitiesof daily living. Currently, no cure for OA is known, and non-pharmacological modalities are recommended as first-line care. A positive effect of exercise in hip and knee OA has been documented, but the effect of exercise on hand OA remains uncertain. To assess the benefits and harms of exercise compared with other interventions, including placebo or no intervention, in people with hand OA. Main outcomes are hand pain and hand function. We searched six electronic databases up until September 2015. All randomised and controlled clinical trials comparing therapeutic exercise versus no exercise or comparing different exercise programmes. Two review authors independently selected trials, extracted data, assessed risk of bias and assessed the quality of the body of evidence using the GRADE approach. Outcomes consisted of both continuous (hand pain, physical function, finger joint stiffness and quality of life) and dichotomous outcomes (proportions of adverse events and withdrawals). We included seven studies in the review. Most studies were free from selection and reporting bias, but one study was available only as a congress abstract. It was not possible to blind participants to treatment allocation, and although most studies reported blinded outcome assessors, some outcomes (pain, function, stiffness and quality of life) were self-reported. The results may be vulnerable to performance and detection bias owing to unblinded participants and self-reported outcomes. Two studies with high drop-out rates may be vulnerable to attrition bias.We downgraded the overall quality of the body of evidence to low owing to potential detection bias (lack of blinding of participants on self-reported outcomes) and imprecision (studies were few, the number of participants was limited and Exercise for hand osteoarthritis (Review) 1 Copyright © 2017 The Cochrane Collaboration. Published by JohnWiley & Sons, Ltd. confidence intervals were wide for the outcomes pain, function and joint stiffness). For quality of life, adverse events and withdrawals due to adverse events, we further downgraded the overall quality of the body of evidence to very low because studies were very few and confidence intervals were very wide. Low-quality evidence fromfive trials (381 participants) indicated that exercise reduced hand pain (standardised mean difference (SMD) -0.27, 95% confidence interval (CI) -0.47 to -0.07) post intervention. The absolute reduction in pain for the exercise group, compared with the control group, was 5% (1% to 9%) on a 0 to 10 point scale. Pain was estimated to be 3.9 points on this scale (0 = no pain) in the control group, and exercise reduced pain by 0.5 points (95% CI 0.1 to 0.9; number needed to treat for an additional beneficial outcome (NNTB) 9). Four studies (369 participants) indicated that exercise improved hand function (SMD -0.28, 95% CI -0.58 to 0.02) post intervention. The absolute improvement in function noted in the exercise group, compared with the control group, was 6% (0.4% worsening to 13% improvement). Function was estimated at 14.5 points on a 0 to 36 point scale (0 = no physical disability) in the control group, and exercise improved function by 2.2 points (95% CI -0.2 to 4.6; NNTB 9). One study (113 participants) evaluated quality of life, and the effect of exercise on quality of life is currently uncertain (mean difference (MD) 0.30, 95% CI -3.72 to 4.32). The absolute improvement in quality of life for the exercise group, compared with the control group, was 0.3% (4% worsening to 4% improvement). Quality of life was 50.4 points on a 0 to 100 point scale (100 = maximum quality of life) in the control group, and the mean score in the exercise group was 0.3 points higher (3.5 points lower to 4.

View all works in Cristin